Publication:
The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis

dc.contributor.authorTuğsal, Handan Yarkan
dc.contributor.authorKenar, Gökce
dc.contributor.authorCan, Gerçek
dc.contributor.authorÇapar, Sedat
dc.contributor.authorZengin, Berrin
dc.contributor.authorAkar, Servet
dc.contributor.authorŞenel, Soner
dc.contributor.authorKoca, Süleyman Serdar
dc.contributor.authorGöker, Berna
dc.contributor.authorYazıcı, Ayten
dc.contributor.authorInanç, Nevsun
dc.contributor.authorEllidokuz, Hülya
dc.contributor.authorAkkoç, Nurullah
dc.contributor.authorÖnen, Fatoş
dc.contributor.buuauthorDalkilic, Ediz
dc.contributor.buuauthorDALKILIÇ, HÜSEYİN EDİZ
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.
dc.contributor.researcheridJHC-5173-2023
dc.date.accessioned2024-11-29T12:38:29Z
dc.date.available2024-11-29T12:38:29Z
dc.date.issued2023-01-01
dc.description.abstractBackground/aim: To investigate the impact of smoking on disease activity, treatment retention, and response in patients with ankylosing spondylitis (AS) treated with their first tumor necrosis factor-alpha inhibitor (TNFi).Materials and methods: AS patients who started their first TNFi treatment for the active axial disease (BASDAI >= 4) from TURKBIO Registry were included. Treatment response of smoker (current and ex-smokers) and nonsmoker (never smoker) patients were primarily evaluated as achievement of BASDAI50 or improvement in BASDAI at least 20 mm at 3 months and 6 months compared to baseline.Results: There were 322 patients with AS (60% male, 59% smoker, mean age: 38.3 years). The median follow-up time was 2.8 years (Q1-Q3: 1.3-3.8), and disease duration was 3.5 years (Q1-Q3: 0.7-8.2). Smokers had male predominance (p < 0.001), lower ESR (p = 0.03), higher BASDAI (p = 0.02), BASFI (p = 0.05), HAQ-AS (p = 0.007), and ASDAS-CRP (p = 0.04) compared with nonsmokers at baseline. In the multivariate analysis, male gender [OR 2.7 (95%CI 1.4-5), p = 0.002], and concomitant conventional synthetic disease-modifying antirheumatic drug use [OR 2.4 (95%CI 1.1-5.2), p = 0.03] were associated with better treatment response. There was an association of male gender [HR 2.4 (95%CI 1.6-3.7), p < 0.001], older age (>= 30years) [HR 1.8 (95%CI 1.1-2.8), p = 0.01], and response to treatment [HR 1.8 (95%CI 1.2-2.9), p = 0.008] with better treatment retention. No impact of smoking status was found on treatment retention and response in univariate and multivariate analyses.Conclusion: This study suggested that smoking was associated with poorer patient-reported outcomes in biologic naive AS patients initiating their first TNFi treatment, but it had no impact on the TNFi treatment response and retention rate.
dc.identifier.doi10.55730/1300-0144.5661
dc.identifier.endpage978
dc.identifier.issn1300-0144
dc.identifier.issue4
dc.identifier.startpage970
dc.identifier.urihttps://doi.org/10.55730/1300-0144.5661
dc.identifier.urihttps://hdl.handle.net/11452/48725
dc.identifier.volume53
dc.identifier.wos001166710900014
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.journalTurkish Journal Of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectQuality-of-life
dc.subjectActivity score asdas
dc.subjectAnti-tnf therapy
dc.subjectDisease-activity
dc.subjectAxial spondyloarthritis
dc.subjectCigarette-smoking
dc.subjectFunctional ability
dc.subjectStructural damage
dc.subjectProgression
dc.subjectSmokers
dc.subjectAnkylosing spondylitis
dc.subjectSmoking
dc.subjectTumor necrosis factor-alpha inhibitor
dc.subjectTreatment response
dc.subjectRegistry
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectMedicine, general & internal
dc.subjectGeneral & internal medicine
dc.titleThe impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication1613225c-2f43-4052-9f82-210c854edcf4
relation.isAuthorOfPublication.latestForDiscovery1613225c-2f43-4052-9f82-210c854edcf4

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Dalkilic_vd_2023.pdf
Size:
487.61 KB
Format:
Adobe Portable Document Format

Collections